ASH 2023 | Immunotherapy with blinatumomab vs chemotherapy in pediatric patients with newly diagnosed B-ALL
Martin Schrappe, MD, University Medical Center Schleswig-Holstein, Kiel, Germany, comments on the Phase III AIEOP-BFM ALL 2017 trial (NCT03643276), which aims to evaluate the toxicity and efficacy of blinatumomab in comparison to conventional chemotherapy in high- and medium-risk pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Initial findings of the study reveal lower toxicity with this agent than conventional chemotherapy in high-risk patients, with efficacy outcomes pending. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
